Sigachi Industries Limited has informed the Exchange about Transcript
SIGACHI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sigachi Industries reported FY25 operating income of INR500 crores, up 25.42% YoY, with EBITDA rising 46.21% to INR112 crores (margin 22.38%) and net profit up 23.25% to INR70.5 crores. The MCC (microcrystalline cellulose) segment drove growth at 35.75% to INR409 crores, while the O&M business grew 17.66% to INR41 crores and the API (active pharmaceutical ingredients) arm contributed INR29 crores. Management guided for 25%+ revenue CAGR over the next 2-3 years, with EBITDA margins expected to move beyond 25%, supported by a 7,000 MTPA new plant at 68% utilization and capacity augmentation to 25,000 MTPA via debottlenecking. The O&M business is targeted to nearly double to INR75 crores in FY26, while a new INR90 crore CCS (croscarmellose sodium) plant at Dahej-2 is expected to commission by October 2026. API expansion includes 4 CEP filings (1 secured for Metformin HCL) and 5 more planned, with API plant utilization at 35-40% and an additional 150 KL capacity being considered.
Positive near-term sentiment from strong FY25 earnings beat and confident multi-year growth guidance, though near-term margin expansion to 'beyond 25%' depends on execution of O&M scaling and CCS plant commissioning by Oct'26. The INR90 crore CCS capex partly funded by INR55-60 crore debt and promoter pledging at 44% (up from 23%) are points to monitor.